Aviso Financial Inc. increased its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 3.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 129,467 shares of the medical research company's stock after purchasing an additional 4,222 shares during the quarter. IQVIA accounts for 1.3% of Aviso Financial Inc.'s investment portfolio, making the stock its 23rd largest position. Aviso Financial Inc. owned approximately 0.07% of IQVIA worth $25,442,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Atala Financial Inc acquired a new position in IQVIA during the fourth quarter worth $91,000. Commonwealth Equity Services LLC raised its stake in shares of IQVIA by 0.6% during the 4th quarter. Commonwealth Equity Services LLC now owns 26,104 shares of the medical research company's stock worth $5,130,000 after buying an additional 157 shares during the last quarter. Thompson Siegel & Walmsley LLC boosted its position in shares of IQVIA by 469.0% in the 4th quarter. Thompson Siegel & Walmsley LLC now owns 126,845 shares of the medical research company's stock worth $24,926,000 after buying an additional 104,553 shares in the last quarter. Erste Asset Management GmbH grew its stake in IQVIA by 0.4% in the 4th quarter. Erste Asset Management GmbH now owns 91,352 shares of the medical research company's stock valued at $18,095,000 after acquiring an additional 332 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in IQVIA by 789.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 227,512 shares of the medical research company's stock valued at $44,708,000 after acquiring an additional 201,945 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.
Wall Street Analysts Forecast Growth
IQV has been the topic of several research reports. Leerink Partners reiterated an "outperform" rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Truist Financial reissued a "buy" rating and set a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Barclays reduced their price objective on IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a research report on Monday, February 3rd. Robert W. Baird cut their target price on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, January 21st. Finally, Stephens started coverage on shares of IQVIA in a research note on Friday, December 20th. They set an "overweight" rating and a $250.00 price target on the stock. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IQVIA currently has an average rating of "Moderate Buy" and an average target price of $249.05.
View Our Latest Research Report on IQVIA
IQVIA Stock Up 1.9 %
IQV stock traded up $3.55 during midday trading on Tuesday, hitting $188.45. 1,344,794 shares of the company's stock were exchanged, compared to its average volume of 1,226,685. The firm has a 50 day moving average price of $196.34 and a 200-day moving average price of $209.96. IQVIA Holdings Inc. has a 12-month low of $179.28 and a 12-month high of $256.34. The stock has a market capitalization of $33.23 billion, a price-to-earnings ratio of 25.13, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.
IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
